MORPHINE PHARMACOKINETICS AND PHARMACODYNAMICS IN SICKLE CELL DISEASE

吗啡在镰状细胞病中的药代动力学和药效学

• 批准号: 8166575
• 负责人: Wally R Smith
• 金额: $ 0.82万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166575
• 关键词: Acute; Address; African American; Age; Analgesics; Cardiovascular system; Caring; Chronic; Cognitive; Communities; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Kinetics; Funding; Gender; Grant; Health Personnel; Institution; Morphine; Opiate Addiction; Opiates; Opioid; Pain management; Participant; Patients; Perception; Pharmacodynamics; Pilot Projects; Population; Race; Research; Research Personnel; Resources; Sickle Cell; Sickle Cell Anemia; Source; Substance Use Disorder; United States National Institutes of Health; Weight; addiction; chronic pain; design; morphine-3-glucuronide; morphine-6-glucuronide; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Healthcare providers' perception of and concern regarding opiate addiction can be major barriers to appropriate care. Further, use of sometimes high doses of opiates for acute and chronic pain management in SCD has led to concerns of inappropriate opiate dependence and addiction. This study address the lack of supportive evidence for determining appropriate opiate prescribing in SCD, we propose a basic pilot study to characterize the pharmacokinetics and pharmacodynamics of morphine in segments of our SCD population. This pilot study will greatly inform the sickle cell community and prepare the ground for larger scale trials of opioid use in SCD To determine the pharmacokinetic (morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) and pharmacodynamic (subjective, cognitive, cardiovascular and analgesic) effects of morphine (IV and PO) using a dose response design in 3 groups: 1. Sickle cell disease patients not treated chronically with opioids, 2. Sickle cell disease patients receiving chronic opioid treatment, 3. Control African-American participants without substance use disorders or current opioid use matched by age, race, gender, and weight.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 医疗保健提供者对阿片成瘾的看法和担忧可能是适当护理的主要障碍。此外，有时使用高剂量的阿片类药物来治疗 SCD 的急性和慢性疼痛，导致人们担心不适当的阿片类药物依赖和成瘾。 这项研究解决了缺乏支持性证据来确定 SCD 适当阿片类处方的问题，我们提出了一项基本的试点研究来表征吗啡在 SCD 人群中的药代动力学和药效学。 这项试点研究将为镰状细胞群体提供重要信息，并为阿片类药物在 SCD 中使用的更大规模试验奠定基础 为了确定吗啡（静脉注射和口服）的药代动力学（吗啡-3-葡萄糖苷酸（M3G）和吗啡-6-葡萄糖苷酸（M6G）和药效学（主观、认知、心血管和镇痛）作用，采用剂量反应设计分三组： 1. 未长期接受阿片类药物治疗的镰状细胞病患者， 2.接受长期阿片类药物治疗的镰状细胞病患者， 3. 对照年龄、种族、性别和体重，控制没有物质使用障碍或当前使用阿片类药物的非裔美国参与者。